Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07023419

Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse

In complex detoxification hospital units, patients receive a common care system (interviews, therapeutic workshops, support for discharges, etc.). In the event of a relapse during hospitalization, i.e., a relapse into addiction, hospital care is called into question, and discharge is generally considered. A key care issue is therefore to prevent these relapses by identifying risk profiles to strengthen their management. According to studies, psychiatric diagnoses increase the risk of relapse, but the investigators do not fully understand which ones or to what extent.

The objective of this study is to analyze the influence of psychiatric diagnoses on the risk of relapse. This would allow for adapting the care of these patients to reduce this risk. The investigators are also seeking to study the value of screening questionnaires in improving the reliability of psychiatric diagnoses.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'Addictologie - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Amaury DURPOIX, MD

CONTACT

[email protected]

33.6.77.90.62.28

Amaury DURPOIX, MD

PRINCIPAL_INVESTIGATOR

François Severac, Statician

SUB_INVESTIGATOR

Hinderer Jeanne-Hélène Hinderer, MD

SUB_INVESTIGATOR

Laurence Lalanne, MD, PhD

SUB_INVESTIGATOR

Lisa Weiss, MD

SUB_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject aged ≥16
  • Having been hospitalized in the complex withdrawal unit of the Strasbourg psychiatric clinic during the period from January 1, 2024 to November 1, 2024

Exclusion criteria

  • Refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. Insomnia Severity Score (ISI)

    Time frame: At 22 months

    The ISI is a scale composed of 7 questions:

    Each of the 7 items is rated on a 5-point Likert scale (from 0 to 4). The total score is obtained by adding the scores for all 7 items (1a+1b+1c+2+3+4+5). The total score ranges from 0 to 28:

    0-7 = No insomnia 8-14 = Subclinical (mild) insomnia 15-21 = Clinical (moderate) insomnia 22-28 = Clinical (severe) insomnia

  2. Depression Scale Score (PHQ 9)

    Time frame: At 22 months

    Depression Scale Score (PHQ 9)

    • Items are rated on a scale from 0 to 3. The maximum score is 27.
    • The threshold for assessing moderate depression (10 or higher) is the most commonly used. • Thresholds:

    No depression: 0-4 points; Mild depression: 5-9 points; Moderate depression: 10-14 points; Moderately severe depression: 15-19 points; Severe depression: 20-27 points.

  3. Anxiety score (GAD-7)

    Time frame: At 22 months

    Anxiety score (GAD-7):

    The total score of the GAD-7 questionnaire ranges from 0 to 21 points. Scores of 5, 10, and 15 represent thresholds for detecting mild, moderate, or severe anxiety:

    Score 0-4: Minimal anxiety Score 5-9: Mild anxiety Score 10-14: Moderate anxiety Score above 15: Severe anxiety

  4. Posttraumatic Stress Disorder Score (PCL-5)

    Time frame: At 22 months

    Posttraumatic Stress Disorder Score (PCL-5):

    The PCL-5 scale assesses the presence and severity of PTSD using 20 items.

    The PTSD severity score ranges from 0 (not present at all) to 4 (extremely), resulting in a total score between 0 and 80. PCL-5 scores were used to determine the presence of PTSD.:

    A score:

    above 33 indicates the presence of PTSD, between 31 and 33 indicates probable PTSD below 31 indicates no PTSD.

  5. Addictions Score (DAST-10)

    Time frame: At 22 months

    Addictions Score (DAST-10):

    The maximum total score is 10. A threshold of 3 or 4 is recommended for screening for a drug use problem. This threshold would most closely match the criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM):

    A score of 9 or higher indicates a severe problem.

  6. ADHD Score

    Time frame: At 22 months

    ADHD Score:

    Points are summed on a scale of 0 to 24, with a threshold of 14 or higher for a positive ADHD screen result. The total score can be categorized into four strata:

    0 to 9 = weakly negative 10 to 13 = strongly negative 14 to 17 = weakly positive 18 to 24 = strongly positive

  7. Autism Score (RAADS-14)

    Time frame: At 22 months

    Autism Score (RAADS-14):

    The RAADS-R test calculates a score indicating the likelihood of an autism spectrum disorder in the individual taking it. The total score on the RAADS-R test ranges from 0 to 240.

    Higher scores indicate behaviors and symptoms consistent with autism. Scores equal to or greater than 65 indicate the presence of autism.

  8. Emotion Dysregulation Score (DERS-16)

    Time frame: At 22 months

    Emotion Dysregulation Score (DERS-16) A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) cognitive reappraisal and (2) expressive suppression. Respondents respond to each item on a 7-point Likert-type scale, ranging from 1 (strongly disagree) to 7 (strongly agree).

Study contacts

Contact information is provided by the study sponsor or research team.

Amaury DURPOIX, MD

CONTACT

[email protected]

33 6 77 90 62 28

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: Psyaddict

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 17, 2025
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.